Diabetes and Beyond: Reducing Co-morbidities with Novel Antidiabetic Agents (CPE Only)

Member Price: $15 | Non-Member Price: $15 | CPE Only

Keyword(s) diabetes and beyond, beyond, diabetes, reducing, co-morbididities, novel, antidiabetic, agents

This interactive, case-based session will review this emerging data along with the most recent American Diabetes Association guidelines to empower pharmacists to make appropriate agent selection for older patients based upon patient specific comorbidities.

Credit CPE:1.5

Tag(s) Supplemental Courses, Webinars On-Demand

Description

TITLE

Diabetes and Beyond: Reducing Co-morbidities with Novel Antidiabetic Agents (CPE Only)

DATE

This activity was pre-recorded on May 25, 2022, at 1pm-2pm EST. Participants must complete the course in its entirety to receive credit for this home study activity.

This home study version was released on June 1, 2022. Each user has 365 days of access post-purchase -OR- its expiration date May 1, 2025, whichever occurs first. *This activity is NOT FL Consultant Approved

ACTIVITY FEE

Free for ASCP Members, $15 Non-Members

PRESENTER
Nicole Early, PharmD, BCPS, BCGP, FASCP

Associate Professor

Midwestern University College of Pharmacy – Glendale

Elizabeth Pogge, PharmD, MPH, BCGP AQ Cardiology, FASCP

Professor

Midwestern University College of Pharmacy - Glendale

FINANCIAL DISCLOSURE

Speakers discloses no relevant financial conflicts of interest with regard to this activity.

ASCP's BCGP webinars are supported in part through a generous grant from the ASCP Foundation

TARGET AUDIENCE
Pharmacists interested in:Diabetes and Beyond: Reducing Co-morbidities with Novel Antidiabetic Agents

COURSE DESCRIPTION

Older adults experience many comorbidities that influence their morbidity and mortality. In recent years, novel antidiabetic agent, including sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists, have demonstrated additional benefits beyond glucose lowering, including reduced cardiovascular risk, improved renal function, and weight loss. This interactive, case-based session will review this emerging data along with the most recent American Diabetes Association guidelines to empower pharmacists to make appropriate agent selection for older patients based upon patient specific comorbidities.

LEARNING OBJECTIVE
At the conclusion of this application-based activity, participants should be able to:

Describe the cardiovascular, renal, and obesity clinical trials for novel antidiabetic agents.
Compare risks and benefits of novel antidiabetic agents in older adults.
Given a patient case, utilize current ADA guidelines and available clinical trial evidence to create a patient care plan with a focus on novel antidiabetic agents in older adults with and without diabetes.

CONTINUING PHARMACY EDUCATION

The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0203-0000-22-026-H01-P

Initial Release Date: June 1, 2022

Credits: 1.5 CPE Contact Hours (1 hour of recorded content, 0.5 hours for post-test assessment)

Expiration: May 1, 2025, by 11:59pm ET

HOW TO EARN CREDIT
Post-Test: You will have 3attempts to achieve a 70% or higher on the post-test assessment.

CPE Credit: You must complete the post-test and evaluation within 365 days post purchase or by the expiration date, whichever occurs first to receive credit. ASCP reports CPE attainment to ACPE and NABP via the CPE Monitor system. The course should be posted within 24-48 hours of evaluation completion. It is the responsibility of the participant to provide their correct date of birth (MMDD format) and NABP e-Profile ID on their member or guest profile on the ASCP Website.

PROVIDER CONTACT INFORMATION
For questions about this educational activity, please contact ASCP at: education@ascp.com

Technical Assistance: Help Page